The Filing Desk

Alkermes vs Spyre Therapeutics

Alkermes ALKS · Spyre Therapeutics SYRE · Pharmaceuticals

Side by side

AlkermesSpyre Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1.5B$0M
Revenue growth−5.2%—
Revenue growth a year, last 5 years7.3%—
Gross margin86.7%—
Operating margin17.2%—
Net margin16.4%—
Free cash flow$480M—
Free cash flow margin32.5%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count−0.3%—
Last close$47.03$104.00
P/E at the last close——
Insider trades, last 12 monthssold $10.0 millionsold $435.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AlkermesSpyre Therapeutics
Operating margin
Percent of revenue
AlkermesSpyre Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlkermesSpyre Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alkermes and Spyre Therapeutics pages.